Capital Investment Advisors Has Upped Its Abbvie (ABBV) Stake; Exact Sciences (EXAS)’s Sentiment Is 1.01

February 19, 2018 - By Clifton Ray

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $5.85 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Capital Investment Advisors Llc increased Abbvie (ABBV) stake by 28.65% reported in 2017Q3 SEC filing. Capital Investment Advisors Llc acquired 7,257 shares as Abbvie (ABBV)’s stock rose 6.17%. The Capital Investment Advisors Llc holds 32,587 shares with $2.90M value, up from 25,330 last quarter. Abbvie now has $189.34B valuation. The stock increased 3.22% or $3.7 during the last trading session, reaching $118.6. About 8.83M shares traded or 48.72% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 19, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on February, 20. They expect $-0.29 EPS, up 14.71% or $0.05 from last year’s $-0.34 per share. After $-0.23 actual EPS reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 26.09% negative EPS growth.

Ratings analysis reveals 33% of EXACT Sciences’s analysts are positive. Out of 3 Wall Street analysts rating EXACT Sciences, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $15.0 while the high is $17.0. The stock’s average target of $16 is -67.25% below today’s ($48.86) share price. EXAS was included in 3 notes of analysts from October 26, 2016. As per Wednesday, February 22, the company rating was upgraded by Roth Capital. The stock has “Hold” rating by Benchmark on Wednesday, October 26. The rating was maintained by Lake Street with “Hold” on Tuesday, November 1.

The stock decreased 0.57% or $0.28 during the last trading session, reaching $48.86. About 1.23 million shares traded. Exact Sciences Corporation (EXAS) has risen 458.24% since February 19, 2017 and is uptrending. It has outperformed by 441.54% the S&P500.

Antipodean Advisors Llc holds 22.96% of its portfolio in Exact Sciences Corporation for 577,346 shares. Zevenbergen Capital Investments Llc owns 2.12 million shares or 4.33% of their US portfolio. Moreover, Sanctuary Wealth Advisors Llc has 3.18% invested in the company for 87,180 shares. The Wisconsin-based Thompson Investment Management Inc. has invested 2.4% in the stock. Elk Creek Partners Llc, a Colorado-based fund reported 762,288 shares.

Since January 1, 0001, it had 0 insider buys, and 8 insider sales for $27.11 million activity.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. BMO Capital Markets downgraded the stock to “Underperform” rating in Tuesday, January 30 report. As per Monday, December 7, the company rating was upgraded by Jefferies. The rating was downgraded by Morgan Stanley on Wednesday, June 8 to “Equal-Weight”. Citigroup upgraded it to “Buy” rating and $65 target in Tuesday, February 23 report. BMO Capital Markets maintained the stock with “Hold” rating in Wednesday, June 7 report. The rating was maintained by Jefferies with “Buy” on Tuesday, January 16. On Friday, December 18 the stock rating was initiated by Atlantic Securities with “Neutral”. The rating was maintained by Jefferies with “Buy” on Monday, May 29. Barclays Capital downgraded the shares of ABBV in report on Tuesday, December 1 to “Equal-Weight” rating. As per Thursday, May 25, the company rating was maintained by Jefferies.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.15, from 1 in 2017Q2. It worsened, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Matarin Mngmt Lc, a Connecticut-based fund reported 40,042 shares. Naples Glob Advisors Llc accumulated 30,979 shares. Bryn Mawr Communication stated it has 40,752 shares or 0.21% of all its holdings. Keybank Association Oh has 1.35M shares for 0.71% of their portfolio. Hartline Inv Corporation owns 0.24% invested in AbbVie Inc. (NYSE:ABBV) for 8,775 shares. Schaper Benz And Wise Investment Counsel Wi reported 0.23% of its portfolio in AbbVie Inc. (NYSE:ABBV). Lsv Asset Mngmt has invested 1% in AbbVie Inc. (NYSE:ABBV). Private Harbour Investment Mgmt & Counsel Lc has invested 1.08% in AbbVie Inc. (NYSE:ABBV). Fisher Asset Management owns 683,274 shares. Kessler Inv Grp Ltd Llc has invested 1.35% of its portfolio in AbbVie Inc. (NYSE:ABBV). Walter Keenan Finance Consulting Communication Mi Adv stated it has 1.44% of its portfolio in AbbVie Inc. (NYSE:ABBV). Wealth Architects Lc owns 6,481 shares or 0.2% of their US portfolio. Rand Wealth Lc has 0.46% invested in AbbVie Inc. (NYSE:ABBV). Rbo And Com Lc, California-based fund reported 109,168 shares. Gyroscope Capital Mngmt Gp Ltd Company, Florida-based fund reported 66,400 shares.

Since September 11, 2017, it had 0 insider purchases, and 5 sales for $25.59 million activity. $14.07M worth of stock was sold by Schumacher Laura J on Thursday, December 14. Gosebruch Henry O also sold $1.66M worth of AbbVie Inc. (NYSE:ABBV) on Monday, October 30. Another trade for 87,040 shares valued at $8.57 million was sold by RICHMOND TIMOTHY J.. Another trade for 8,300 shares valued at $705,655 was made by SALEKI-GERHARDT AZITA on Monday, September 11. $589,512 worth of AbbVie Inc. (NYSE:ABBV) was sold by Michael Robert A. on Thursday, September 28.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: